Showing 2781-2790 of 5974 results for "".
- Early Botox Improves Final Appearance in 'Split-Scar' Studyhttps://practicaldermatology.com/news/early-botox-treatment-improves-final-appearance-in-split-scar-study/2457856/Early injections of botulinum toxin A can improve the final appearance of surgical scars, according to a study in the March issue of Plastic
- Galderma Enters into Long-term Research Agreement on AD with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicinehttps://practicaldermatology.com/news/galderma-enters-into-long-term-research-agreement-on-ad-with-icahn-school-of-medicine-at-mount-sinai-and-northwestern-university-feinberg-school-of-me/2457865/Galderma has signed a joint research agreement on Atopic Dermatitis (AD) with two leading academic institutions—Icahn School of Medicine at Mount Sinai in New York City, and Northwestern University Feinberg School of Medicine in Chicago. This seven-year collaborative agreement aims to enhan
- Thermi and Sinclair Terminate Collaboration on Silhouette Instalifthttps://practicaldermatology.com/news/thermi-and-sinclair-terminate-collaboration-on-silhouette-instalift/2457866/Thermi, an Almirall S.A. company, and Sinclair Pharma have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift. Both companies have been working through a join
- ISDIN AGE Contour Launches for Face and Neckhttps://practicaldermatology.com/news/isdin-age-contour-launches-for-face-and-neck/2457869/ISDIN has launched ISDIN AGE Contour, a triple action face and neck cream packed with ingredients to fight three key aspects of skin aging. Formulated with a tripeptide complex con
- New DermTech Research Validates Gene Expression Against High-Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanomahttps://practicaldermatology.com/news/new-dermtech-research-validates-gene-expression-against-high-risk-dna-mutations-providing-objective-information-for-the-diagnosis-of-melanoma/2457871/DermTech, Inc. presented a late breaking abstract—“Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver Mutations (BRAF, NRAS, and TERT) in Cutaneous Melanoma” —at the 76th Annual Meeting of the American Academy of Dermatology (AAD) in San Di
- Asthma and Allergy Foundation Study Shows High Prevalence and QoL Impact for Adults with Atopic Dermatitishttps://practicaldermatology.com/news/asthma-and-allergy-foundation-study-shows-high-prevalence-and-qol-impact-for-adults-with-atopic-dermatitis/2457872/The Asthma and Allergy Foundation of America (AAFA) shared data demonstrating the high rate of prevalence of atopic dermatitis (AD) in the US adult population and a greater impact on health-related quality of life and mental health symptoms, such as depression and anxiety, for patients with moder
- Some Parents Just Don't Understand Risks of Indoor Tanninghttps://practicaldermatology.com/news/some-parents-just-dont-understand-risks-of-indoor-tanning/2457878/Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents&rs
- Stelara Reduces Aortic Vascular Inflammationhttps://practicaldermatology.com/news/stelara-reduces-aortic-vascular-inflammation/2457880/In addition to its effects on skin inflammation, Stelara (Ustekinumab) reduces aortic inflammation, report researchers from the Perelman School of Medicine at the University of Pennsylvania at the annual meeting of the American Academy of Dermato
- Denova Research and Illinois Dermatology Institute Partner for Clinical Researchhttps://practicaldermatology.com/news/denova-research-and-illinois-dermatology-institute-partner-for-clinical-research/2457894/DeNova Research is partnering with Illinois Dermatology Institute to become one of the largest and most comprehensive Dermatologic and Cosmetic Clinical Research sites in the Midwest. Denova Research has over 10 years’ experience, 110 publications and 76 clinical trials; many of whi
- FDA Approves Cosentyx Label Update to Include Scalp Psoriasishttps://practicaldermatology.com/news/fda-approves-cosentyx-label-update-to-include-scalp-psoriasis/2457896/The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label includes Cosentyx data in moderate to severe scalp psoriasis—one of the difficult-to-treat for